Modulating NLRP3 splicing with antisense oligonucleotides to control pathological inflammation
Nucleic Acids Research · 28.10.2025 · 53 (20)
DOI: 10.1093/nar/gkaf1116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 07.11.2025. Verfasst von Roni Klein und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Genetic Diseases, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, United States. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Oligonucleotides, Antisense, Inflammation, Alternative Splicing. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, University of Michigan, National Institutes of Health.
Abstract (Originalsprache)
Inflammation has an essential role in healing. However, over-active inflammation disrupts normal cellular functions and can be life-threatening when not resolved. The NLR family pyrin domain-containing 3 (NLRP3) inflammasome, a component of the innate immune system, is an intracellular multiprotein complex that senses stress-associated signals, and, for this reason is a promising therapeutic target for treating unresolved, pathogenic inflammation. Alternative splicing of NLRP3 RNA has been suggested as a regulatory mechanism for inflammasome activation, as some spliced isoforms encode NLRP3 proteins with compromised function. Here, we take advantage of this natural regulatory mechanism and devise a way to control pathogenic inflammation using splice-switching antisense oligonucleotides (ASOs). To identify and induce NLRP3 isoforms lacking inflammatory activity, we tested a series of ASOs, each targeting a different exon, to determine the most effective strategy for downregulating NLRP3. We identify several ASOs that modulate NLRP3 splicing, reduce NLRP3 protein, and decrease inflammasome signaling in vitro. The most effective ASO suppresses systemic inflammation in vivo in mouse models of acute inflammation and cryopyrin-associated periodic syndrome. Overall, these results demonstrate how ASOs can be used to systematically engineer proteins with modified functions and treat pathological inflammation in mice by reducing functional NLRP3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Genetic Diseases, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, United States.
- School of Graduate and Postdoctoral Studies, Rosalind Franklin University of Medicine and Science, North Chicago, IL 60064, United States.
- Department of Pediatrics, University of California San Diego, La Jolla, CA 92093, United States.
- Department of Pharmacology, University of Michigan Medical School, Ann Arbor, MI 48109-5632, United States.
- Department of Medicine, University of California San Diego, La Jolla, CA 92093, United States.
ORCID-Profile: Roni Klein, Michelle L Hastings
Förderung
- NIH HHS
- University of Michigan
- National Institutes of Health
Zitieren
APA
Klein, R., Onyuru, J., Centa, J. L., Viera, E. M., Putnam, C. D., Hoffman, H. M., & Hastings, M. L. (2025). Modulating NLRP3 splicing with antisense oligonucleotides to control pathological inflammation. Nucleic Acids Research, 53(20). https://doi.org/10.1093/nar/gkaf1116
Vancouver
Klein R, Onyuru J, Centa JL, Viera EM, Putnam CD, Hoffman HM, et al. Modulating NLRP3 splicing with antisense oligonucleotides to control pathological inflammation. Nucleic Acids Research. 2025;53(20). doi:10.1093/nar/gkaf1116
BibTeX
@article{Klein2025,
author = {Klein, Roni and Onyuru, Janset and Centa, Jessica L and Viera, Estela M and Putnam, Christopher D and Hoffman, Hal M and Hastings, Michelle L},
title = {Modulating NLRP3 splicing with antisense oligonucleotides to control pathological inflammation},
journal = {Nucleic Acids Research},
year = {2025},
volume = {53},
number = {20},
doi = {10.1093/nar/gkaf1116}
}
EUVIMED